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Edited by Varda RotterAbstract The eﬀect of surfactin on the proliferation of LoVo
cells, a human colon carcinoma cell line, was examined. Surfac-
tin strongly blocked the proliferation of LoVo cells by inducing
pro-apoptotic activity and arresting the cell cycle, according to
several lines of evidence on DNA fragmentation, Annexin V
staining, and altered levels of poly (ADP-ribose) polymerase,
caspase-3, p21WAF1/Cip1, p53, CDK2 and cyclin E. The anti-pro-
liferative activity of surfactin was mediated by inhibiting extra-
cellular-related protein kinase and phosphoinositide 3-kinase/
Akt activation, as assessed by phosphorylation levels. Therefore,
our data suggest that surfactin may have anti-cancer properties
as a result of its ability to downregulate the cell cycle and sup-
press its survival.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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A subtle balance between cell proliferation and death is
absolutely necessary for keeping physiologically normal cell
growth, whereas aberrant upregulation of cell proliferation is
linked to tumorigenesis and cancerous states. For cell prolifer-
ation, cell cycle must progress properly. The activation of
cyclin-dependent kinases (CDKs 4/6, 2, and 1) via binding
to cyclins (D, E, A and B) and the phosphorylation of E2F
and retinoblastoma are required for cell cycle progression
[1,2]. CIP/KIP family members (p21WAF1/Cip1, p27KIP1 and
p57KIP2) are involved in negatively controlling the formation
of the CDK4/6-cyclin D complex, reducing its kinase activity
in p53-dependent or independent manners during the G1/S
phase of the cell cycle [3].Abbreviations: CDKs, cyclin-dependent kinases; ERK, extracellular-
related protein kinase; IKK, IjB kinase; JNK, C-Jun N-terminal
kinase; MAPK, mitogen-activated protein kinase; PARP, poly (ADP-
ribose) polymerase; PI3K, phosphoinositide 3-kinase
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doi:10.1016/j.febslet.2007.01.059Apoptosis is a fundamental form of cell death that occurs
without inducing inﬂammation. This event is readily distin-
guished by morphological and biochemical features, such as
membrane blebbing and internucleosomal DNA cleavage
[4,5]. Pro-apoptotic events are managed by two diﬀerent path-
ways, extrinsic and intrinsic pathways [6]. The death receptor
complex [Fas ligands and CD95 (APO-1/Fas)]-mediated cellu-
lar process linked to caspase-8 and caspase-3 is a typical extrin-
sic pathway. Intrinsic pathway is triggered by internal death
signals managed by mitochondrial components such as cyto-
chrome c together with Apaf-1. These two pathways come
together at caspase-3 and this cleavage enzyme mediates vari-
ous biochemical and morphological changes via cleaving intra-
cellular substrates such as poly (ADP-ribose) polymerase
(PARP), a sensitive marker of caspase-mediated apoptosis [7].
Intracellular signals regulating cell survival and death are
now largely understood, owing to numerous studies. Of the
signaling molecules, phosphoinositide 3-kinase (PI3K), Akt,
mitogen-activated protein kinases (MAPK) [such as extracellu-
lar-related protein kinase (ERK), p38 and C-Jun N-terminal
kinase (JNK)] and IKK (IjB kinase)/IjB/nuclear factor
(NF)-jB are regarded as important components in regulating
the expression level and activation of apoptosis- and cell
cycle-regulating proteins, including p21WAF1/Cip1, Bcl-2, p53,
cyclin E and CDK [8,9].
Surfactin (M.W.: 1036 Da) is a cyclic lipopeptide biosurfac-
tant containing heptapeptide (LLDLLDL) and a beta-hydroxy
fatty acid. This biosurfactant has been reported to possess var-
ious biological activities, such as anti-mycoplasma, anti-viral,
anti-ﬁbrinogenic, anti-hypercholesterolemic and anti-inﬂam-
matory functions [10–13]. Although surfactin is considered to
be a potential antitumor agent [14], its particular eﬀects on
cancer cells have not yet been proven. How this molecule
can be eﬀective in various biological events is still largely
unknown, however, it is speculated that the structural and
lipophilic properties of surfactin may aﬀect the stability of
biological membranes.
In the previous study, we identiﬁed several bioactive metab-
olites displaying anti-inﬂammatory, anti-cancer and anti-angi-
ogenesis (unpublished data) activities from Korean traditional
shrimp-fermented foods. One of these metabolites was found
to be surfactin produced from a bacterium, Bacillus subtilis
strain JKK238. In the present study, therefore, we aimed to
explore the anti-proliferative activity (cell cycle arrest andblished by Elsevier B.V. All rights reserved.
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cer (LoVo) cells and its anti-cancer mechanism at molecular
levels in detail. This study is the ﬁrst report of the anti-cancer
activity of bacterium-derived biosurfactant assessed at the
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Fig. 1. Eﬀect of surfactin on the viability of LoVo cells. LoVo cells
were cultured in RPMI 1640 medium together with the indicated
concentrations of surfactin for several days. The survival of surfactin-
treated cells was measured by MTT assay. Data represent mean-
s ± S.E.M. of three independent observations performed in triplicate.
*: P < 0.05 and **: P < 0.01 compared to normal.2. Materials and methods
2.1. Materials
Surfactin and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide] were purchased from Sigma Chemical Co. (St.
Louis, MO). SP600125 (a JNK inhibitor), SB203580 (a p38 inhibitor),
U0126 (an ERK inhibitor), wortmannin (a PI3K inhibitor) and
LY294002 (a PI3K inhibitor) were obtained from Calbiochem. (San
Diego, CA). Antibodies to ERK, p38, JNK, Akt, cleaved caspase-3
(Asp175), cleaved PARP (Asp214) and b-actin, and phospho-speciﬁc
antibodies to ERK, p38, JNK, IjBa, Akt and p85 were purchased
from Cell Signaling Technology (Beverly, MA). Antibody to PARP
was from BD Pharmingen (San Diego, CA). LoVo cells, the human
colon cancer cell line, cultured in RPMI 1640 supplemented with
10% FBS and antibiotics [penicillin (100 U/ml)/streptomycin (100 lg/
ml)] without mycoplasma contamination, were purchased from ATCC
(Manassas, VA).
2.2. Cytotoxicity assay
See Supplementary Materials.
2.3. Reverse transcription polymerase chain reaction (RT-PCR)
See Supplementary Materials.
2.4. Phase-contrast microscopy and DAPI staining
See Supplementary Materials.
2.5. Annexin V staining
See Supplementary Materials.
2.6. DNA fragmentation assay
See Supplementary Materials.
2.7. Immunoblotting
See Supplementary Materials.
2.8. Statistical analysis
See Supplementary Materials.3. Results
3.1. Surfactin inhibits the growth of human colon cancer cells
To assess the inhibitory eﬀect of surfactin on the growth of
human colon cancer cells, LoVo cells were treated with surfac-
tin at dosages ranging from 0 to 80 lM, for 12, 24, and 48 h,
and MTT assay was conducted. As shown in Fig. 1, compared
with untreated cells, cells treated with 80 lM surfactin for 24
and 48 h underwent almost 80% death, and 30 lM surfactin
treatment for 24 h also displayed signiﬁcant anti-proliferative
activity. These results indicate that surfactin could suppress
the proliferation of LoVo cells in dose- and time-dependent
manners. In addition, two other cell lines (RAW264.7 and
U937 cells) were also shown to be dose-dependently sup-
pressed by surfactin treatment (data not shown), suggesting
that the surfactin-mediated inhibition of cancer cell viability
is not cell-speciﬁc. To address whether surfactin was capable
of inducing apoptosis of LoVo cells, a sub-optimal concentra-
tion (30 lM), resulting in 50% inhibition at 2-day incubation
was used for all further experiments.3.2. Eﬀect of surfactin on the induction of pro-apoptotic activity
To evaluate whether the surfactin-induced anti-proliferative
eﬀect was due to mediating its pro-apoptotic activity, several
apoptotic parameters such as DNA fragmentation, morpho-
logical changes, and alteration of membrane polarity were cho-
sen and carefully observed. Surfactin dose-dependently
increased a characteristic DNA ladder pattern, seen in apopto-
tic cell death (data not shown). Clear morphological changes
(nuclear condensation and the presence of perinuclear apopto-
tic bodies) of LoVo cells treated with surfactin (30 lM) were
also observed by conventional microscopy and DAPI staining
(data not shown). Furthermore, early and late-stage apoptotic
cells were detected from 3 to 24 h after surfactin treatment
(30 lM) (Fig. 2), according to Annexin V staining, which
detects translocation of phosphatidylserine (PS), seen in the
alteration of plasma membrane polarity.
3.3. Eﬀect of surfactin on the expression of Fas/Fas ligand and
the activation of caspase-3 and PARP
To study the involvement of death-receptor proteins in the
surfactin-induced apoptotic process, RT-PCR analysis of Fas
and its ligand was performed. The mRNA expression level
of Fas receptor/ligand was increased in a dose-dependent man-
ner, while there was no signiﬁcant change of Bax expression
(Fig. 3A). To demonstrate their involvement in surfactin-med-
iated apoptosis, two key molecules (cleaved caspase-3 and
PARP, a target of caspase-3) in downstream caspase-3 events
were determined. As shown in Fig. 3B, the cleaved level of cas-
pase-3 in LoVo cells was increased dose-dependently by surfac-
tin exposure. PARP-cleaved fragment (85 kDa) was also seen
after surfactin treatment, similarly.
3.4. Eﬀect of surfactin on the regulation of cell cycle and
the expression level of cell cycle regulatory proteins
To address whether surfactin was able to arrest the cell cycle
of LoVo cells, ﬂow cytometric analysis was employed after PI
staining. As shown in Fig. 4A and B, surfactin increased G1
phase cells up to 10% and, in agreement, the number of cells
in S phase also decreased. Continuously, we next analyzed
the molecular alteration of cell cycle regulatory proteins at
the transcriptional level. As shown in Fig. 4C, surfactin treat-
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Fig. 2. Eﬀect of surfactin on the induction of apoptosis. Cells were treated with 30 lM surfactin for 24 h and collected to conduct Annexin V-
Propidium Iodide assay as described in Section 2. (Left panel) A representative of ﬂow cytometric analysis at 0, 3, 6, 12 and 24 h of treatment. The
horizontal (FL1-Annexin V) and vertical (counts) axes represent labeling with Annexin V and cell number, respectively. (Right panel) Percentages of
the total cell population were plotted against normal healthy cells (Annexin V, PI), early apoptotic cells (Annexin V+, PI), and late apoptotic
cells (Annexin V+, PI+). Results show one representative experiment of 3 with similar results.
S. Kim et al. / FEBS Letters 581 (2007) 865–871 867ment increased transcriptional levels of the p53 tumor suppres-
sor gene and its downstream eﬀector protein p21WAF1/Cip1 at
24 h. Moreover, of cell cycle regulatory proteins such as cyclin
D1, cyclin E, CDK2 and CDK4/6, promoting G1 phase pro-
gression, cyclin E and CDK2 were found to be decreased after
surfactin treatment, whereas cyclin D1 was unchanged (data
not shown). Several technical approaches (using several con-
centrations of diluted RNA and various reaction cycles in pre-
paring total cDNA and PCR products) to ensure the
quantitative accuracy of the mRNA analysis displayed very
similar expression pattern (data not shown).
3.5. Eﬀect of surfactin on the activation of apoptosis-regulatory
signals
Since it has been reported that some signaling enzymes such
as MAPK and PI3K/Akt are known to play a central role in
regulating pro-apoptotic processes including cell cycle arrest,
the modulatory eﬀect of surfactin on the activation of these
enzymes was examined by determining their phosphorylationlevels. Interestingly, surfactin very potently blocked the activa-
tion of all MAPKs (Fig. 5A), without any striking alteration of
total MAPKs. Furthermore, this compound also suppressed
the early activation of PI3K, as judged by the phosphorylation
of p85, and the downstream Akt. To obtain an idea as to
which signals are directly linked to cell proliferation, known
inhibitors of these enzymes were employed under the condi-
tions obtained from lipopolysaccharide-treated macrophages
(data not shown). Fig. 5C shows that three inhibitors
(U0126, wortmannin and LY294002) strongly aﬀected the
viability of LoVo cells, suggesting that ERK and PI3K/Akt
pathways may play important roles in the pro-apoptotic activ-
ity of surfactin.4. Discussion
Emerging evidence has demonstrated that the anticancer
activities of certain chemotherapeutic agents are involved in
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Fig. 4. Eﬀects of surfactin on the induction of cell cycle arrest and the expression of cell cycle regulatory molecules. (A and B) Cells were treated with
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Fig. 3. Activation of caspase-3 and cleavage of PARP by surfactin. (A) RT-PCR: Cells were incubated with the indicated concentrations of surfactin
for 24 h. The mRNA expression levels of Fas, FasL, and Bcl-2 were analyzed by RT-PCR analysis, as described in Section 2. GAPDH was used as a
control. Relative intensity (RI) was calculated by a ratio of GAPDH band intensity. (B) Immunoblotting: Cells were treated with 15 and 30 lM
surfactin for 24 h and Western blot analysis was performed with speciﬁc antibodies raised against cleaved caspase-3 and PARP. An anti-PARP
antibody that recognizes the uncleaved (116 kDa) and cleaved (89 kDa) PARP polypeptides and a cleaved caspase-3 antibody (35 kDa, 17 kDa) were
used. Results (A and B) show one representative experiment of 3 with similar results.
868 S. Kim et al. / FEBS Letters 581 (2007) 865–871the induction of apoptosis and cell cycle arrest, which are
regarded as preferred techniques to manage cancer [15,16].
In this study, we found that surfactin displayed these twoanti-cancer properties. Thus, surfactin strongly inhibited the
proliferation of LoVo cells in a time- and dose-dependent
manner (IC50 value at 48 h incubation = 26 lM) (Fig. 1).
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Fig. 5. Eﬀects of surfactin on the activation of cell survival-regulating
proteins. (A) MAPK activation: Cells (5 · 106) were treated with
30 lM surfactin for the indicated times. Immunoblotting was per-
formed as described in Section 2. Activation of MAPKs (ERK, p38
and JNK) was determined using phosphospeciﬁc antibodies. (B) PI3K/
Akt activation: The activation of PI3K and Akt was determined using
phosphospeciﬁc antibodies. Results (A and B) show one representative
experiment of 3 with similar results. (C) Cytotoxicity of signaling
enzyme inhibitors: LoVo cells were cultured in RPMI 1640 medium
with various signaling enzyme inhibitors [SP600125 (25 lM),
SB203580 (25 lM), U0126 (25 lM), wortmannin (25 lM) and
LY294002 (50 lM)] for indicated times. The survival of surfactin-
treated cells was measured by MTT assay. Results are expressed as
percentage of growth. Data represent means ± S.E.M. of three
independent observations performed in triplicate. *: P < 0.05 and **:
P < 0.01 compared to normal.
S. Kim et al. / FEBS Letters 581 (2007) 865–871 869Inhibitory potency (IC50 values) was shown to be similar to
other cell lines (Molt, Hep 2, H9, Vero, MT-4 and 293 cells),
ranging from 30 to 65 lM [12,17]. Surfactin-mediated anti-cancer eﬀects were demonstrated by several lines of evidence.
It induced DNA fragmentation as assessed by gel electropho-
resis (data not shown), stimulated morphological changes as
assessed by microscopy and DAPI staining (data not shown),
enhanced the loss of plasma membrane polarity as demon-
strated by Annexin V staining (Fig. 2), and altered the levels
of apoptosis- and cell cycle-regulatory proteins (upregulation:
Fas receptor, Fas ligand, cleaved PARP, cleaved caspase-3,
p21WAF1/Cip1 and p53, and downregulation: CDK2 and cyclin
E) (Figs. 3 and 4) in a time- and dose-dependent manner.
The extrinsic CD95 (APO-1/Fas) pathway is initiated by
activation of caspase-8 resulting in its direct cleavage of down-
stream eﬀector caspases (e.g. caspase-3) [7]. In contrast, the
intrinsic apoptotic pathway is carried out by the activation
of caspases through pro-apoptotic factors released from the
mitochondrial intermembrane space [7]. Cells that die via the
CD95 pathway without the involvement of mitochondria are
called Type I cells, whereas cells in which CD95-mediated
death relies mostly on the intrinsic pathway are called Type
II [18]. Our study showed that the mRNA expression levels
of Fas and its ligand were signiﬁcantly increased in surfactin-
treated LoVo cells. This result, therefore, led us to suggest that
the enhancement of Fas by surfactin may be beneﬁcial for
restoring apoptotic sensitivity of LoVo cells to chemotherapy.
Furthermore, activation of caspase-3 and PARP cleavage were
obvious after surfactin treatment and the level of Bax, a crucial
mediator for mitochondrial pathway-mediated apoptosis [19],
was not altered, suggesting that the type I cell death receptor
signaling (extrinsic) pathway is probably involved in surfac-
tin-induced apoptosis.
Surfactin treatment (30 lM) for 24 h increased G0/G1 phase
cells up to 10% according to cell cycle analysis (Fig. 4A and B).
Considering that 30 lM of surfactin resulted in cytotoxicity up
to 30% and made 40% of total cells apoptotic, almost 30–25%
of cytostatic cells may be cell cycle-arrested under these condi-
tions. The cell cycle is tightly regulated by cell cycle regulatory
proteins (cyclins, CDKs, and CDK inhibitors such as
p21WAF1/Cip1) [3,20]. In particular, cyclin/CDK complexes are
negatively modulated by CDK inhibitors and indeed,
p21WAF1/Cip1, a representative of CDK inhibitor proteins, is
known to be required for cell cycle arrest at G1 phase [3,20]
Moreover, the upregulation of p21WAF1/Cip1 is reported to be
modulated by p53, although a p53-independent manner has
been reported [21,22]. In our results, we found that both
p21WAF1/Cip1 and p53 were strikingly induced by surfactin
treatment, suggesting that surfactin-induced cell cycle arrest
may be mediated by these proteins.
How surfactin is able to induce eﬀective anti-proliferative
activity by cell cycle arrest and pro-apoptotic activities is not
yet clear in this study. However, evidence that surfactin
strongly blocked upstream signaling cascades (Fig. 5) involved
in regulating apoptosis and cell cycle progression led us to con-
sider that surfactin may be a strong signaling blocker. Thus, it
potently blocked the activation of all MAPKs and other sur-
vival-regulating proteins (such as PI3K and Akt) except IjBa,
as assessed by their phosphorylation levels (Fig. 5). Due to
diﬀerential involvement of these proteins in regulating cell
survival and proliferation in a cell-type speciﬁc manner,
signaling enzymes important to LoVo cell viability were exam-
ined using speciﬁc enzyme inhibitors. Of them, three inhibitors
(U0126, wortmannin and LY294002) but not SP600125 and
SB203580 diminished LoVo cell survival, suggesting ERK
870 S. Kim et al. / FEBS Letters 581 (2007) 865–871and PI3K pathways may be involved in the viability of LoVo
cells (Fig. 5C). In particular, inhibition with PI3K inhibitors
was greater than that with the ERK inhibitor during early re-
sponses (at days 1 and 2). Although (1) the activation of ERK,
p38 and p85 was seen at 6 h and (2) surfactin-mediated inhibi-
tion of ERK and p85 phosphorylation appeared at 6 h, previ-
ous reports that ERK is activated by the PI3K/Akt pathway
through Raf-1 [23] and the suppressive pattern of LoVo cell
viability by inhibitors suggest that the PI3K/Akt pathway
may be activated earlier than ERK. The involvement of these
signaling proteins in regulating cell survival and death is well
understood. Thus, the activation of PI3K leads to activation
of Akt. This enzyme then catalyzes both the phosphorylation
of p21 (directly or indirectly via GSK-3) and Raf-1 to regulate
cell cycle progression [24,25]. In addition, phosphorylated Akt
stimulates Raf-1 and IKK to trigger the expression of anti-
apoptotic proteins via the mediation of transcription factors
CREB and NF-jB [23,26]. Furthermore, ERK activation is
also known to be connected to the positive regulation of cell
cycle progression (the G1 phase cells to S phase entry) by the
increase of cyclin-CDK complexes, activation of retinoblas-
toma and up-regulation of E2F family transcription factors
[23,26,27]. Therefore, considering these previous reports,
interruption of these mechanisms by surfactin appears to sig-
niﬁcantly contribute to the anti-cancer activities of this
compound.
The remarkable modulation of cell survival and death sig-
naling by surfactin seems to occur by its intense membrane ef-
fects. Thus, surfactin has been known to display detergent-like
activity on cell membranes. Biophysical study has revealed that
hydrophobic residues of the peptide moiety penetrate rather
deeply into the membrane interface, leading to membrane per-
meabilization but not surface activity [17]. At higher concen-
trations, in particular, this detergent-like activity was
strikingly observed to stabilize leaks due to the compound’s
ability to make multiple-structured polymers [17]. Although
it is not yet clear whether the sub-optimal concentration
(30 lM) of surfactin aﬀects membrane stability, cell morphol-
ogy (data not shown) and ﬂow cytometric proﬁles (Fig. 2) of
surfactin-treated cells did not appear to be leaky and/or lysed.
Rather, we propose that surfactin may be acting as a molecule
disturbing a biochemical phenomenon that occurs at a speciﬁc
site (e.g. lipid raft) of the membrane [28]. In particular, struc-
tural features such as a long chain fatty acid are assumed to act
as a pseudosubstrate (like a PIP3 or a farnesyl group) for either
the PI3K/Akt or farnesyltransferase/Ras/ERK pathway
[29,30]. Indeed, we found that surfactin selectively suppressed
LPS-induced ERK activation (data not shown), suggesting
that it does not simply induce damage of the cell membrane,
but regulates membrane attachment of Ras-GTP. To verify
this possibility, however, several experiments to obtain more
direct evidence must be performed.
In summary, we show that surfactin strongly inhibited cell
proliferation and induced apoptosis of colon cancer LoVo
cells. Apoptotic analyses by Annexin V staining, DNA frag-
mentation, DAPI staining RT-PCR and Western blot con-
ﬁrmed that growth inhibition by surfactin was due to
apoptosis induction and cell cycle progression arrest via the
suppression of cell survival-regulating signals such as ERK
and PI3K/Akt. Therefore, our results provide persuading evi-
dence that surfactin may be considered as a new class of
anti-cancer drugs.Acknowledgment: This work was supported by a grant (No.
201065032SB010) from Agricultural R&D Promotion Center of
Korea.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.2007.
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